Synbody Biotechnology, Inc.
400 Farmington Avenue
Call Box 107
Farmington, CT 06032
Paul Hallenbeck, Ph.D. – President & CEO
Synbody Biotechnology (SBI) is commercializing a disruptive technology for discovery and engineering of high affinity ligands for biotechnology and pharmaceutical applications. Synbodies (synthetic antibodies) are fully synthetic, peptidomimetic molecules that can be rapidly engineered utilizing a proprietary platform technology to control affinity, selectivity and other desirable features. These features enable Synbodies to overcome many limitations of monoclonal antibodies (MAbs) and other ligands as therapeutics and in specific non-therapeutic applications, such as bioprocessing, imaging, and agribusiness, where MAbs are inadequate. SBI has an exclusive worldwide license for commercialization of the Synbody technology.
SBI is an operational company headquartered in a capital-efficient state-of-the-art incubator laboratory at the University of Connecticut Health Center in Farmington, CT. Management includes significant scientific, commercial and financing experience in biotechnology R&D. SBI is currently marketing its ligand discovery services to industry partners and pursuing in-house product development for both therapeutic and non-therapeutic markets.
Creation of ligands that bind with high affinity and specificity to a target of interest is critical across the medical, biomanufacturing and biotechnology industries. Current methodologies to create and produce ligands, including MAbs, represent major bottlenecks and cost drivers for product development, due to 1) slow discovery and optimization, 2) complex manufacturing and QC, 3) poorly immunogenic targets, and 4) complex IP landscape. Thus, there is high demand for MAb alternatives with few options available.
Synbody technology is an in vitro ligand development platform that enables the controlled engineering of fully synthetic peptidomimetic ligands with customizable binding properties. Synbodies are low molecular weight and multivalent and offer a streamlined development process based on a systematic sequence variation approach. This process is rapid and cost-effective and enables simultaneous optimization of multiple molecular properties. Synbodies have demonstrated:
- Customizable high affinity / high specificity binding
- Full modularity for functionalization
- POC for affinity purification and target detection in ELISA, pull-down, Western blot and live cell immunocytochemistry
- Stability under harsh conditions that denature MAbs
- Novel binding mode to address difficult targets
- Capability to cross biological membranes
These key differentiating factors provide SBI with the capability to develop next-generation biotechnology tools and pharmaceuticals.
CT Employees: 4
World Employees: 4